Influenza A Infections Pipeline Insights 2016 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/9k2dcb/influenza_a) has announced the addition of the "Influenza A Infections-Pipeline Insights, 2016" report to their offering.

Influenza A Infections-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Influenza A Infections. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Influenza A Infections.

The report also assesses the Influenza A Infections therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Influenza A Infections
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Influenza A Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Influenza A Infections and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Influenza A Infections Overview
  2. Influenza A Infections Pipeline Therapeutics
  3. Influenza A Infections Therapeutics under Development by Companies
  4. Influenza A Infections Filed and Phase III Products
  5. Comparative Analysis
  6. Influenza A Infections Phase II Products
  7. Influenza A Infections Phase I and IND Filed Products
  8. Influenza A Infections Discovery and Pre-Clinical Stage Products
  9. Influenza A Infections - Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Influenza A Infections - Discontinued Products
  15. Influenza A Infections - Dormant Products
  16. Companies Involved in Therapeutics Development for Influenza A Infections

For more information visit http://www.researchandmarkets.com/research/9k2dcb/influenza_a

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases